Zymeworks

pay deal hand over cash licensing transaction money
Pharma

Zymeworks pivots to become 'royalty-driven' drugmaker

Having found success with its out-licensed cancer med Ziihera, Zymeworks will apply the framework for that drug to all its products going forward.
Fraiser Kansteiner Nov 18, 2025 8:25am
Ziihera

Jazz chalks up another win with HER2 drug Ziihera

Nov 17, 2025 10:28am